{
  "id": 19160910,
  "title": "Zura reports Phase 2 flop in painful skin disorder, stock nosedives",
  "url": "https://urgent.news/2026/11/09/zura-reports-phase-2-flop-in-painful-skin-disorder-stock-nosedives",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-09T13:44:28.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/zura-reports-phase-2-flop-in-painful-skin-disorder-stock-nosedives/"
  },
  "original_language": "en",
  "account": null,
  "summary": "A small biotech’s stock collapsed after the company reported a Phase 2 failure in a debilitating skin condition. Zura Bio said Monday morning that both doses of its experimental drug tibulizumab fared no better than ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Zura Bio’s tibulizumab fails phase 2 trial for skin disease",
        "url": "https://urgent.news/2026/11/09/zura-bios-tibulizumab-fails-phase-2-trial-for-skin-disease",
        "published": "2026-11-09T12:24:48.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}